In the U.S., they are not FDA-approved for human use but are available for research purposes
A 2017 study by Hsieh and colleagues in Journal of Molecular Medicine reported that BPC-157, in chick chorioallantoic membrane, rat hind-limb ischemia, and HUVEC models, directionally increased vessel density, accelerated blood-flow recovery in ischemic muscle, and time-dependently activated the VEGFR2-Akt-eNOS signaling pathway via VEGFR2 internalization a mechanistic preclinical finding for which numeric effect sizes are not reported in the abstract
In one study, 36.3% of such patients had anti-TPO, 25% had anti-TG, and 20.2% had both
Avoid -80C, which provides no additional benefit and complicates retrieval
This increases blood flow to damaged tissues, allowing them to heal faster
For context, the placebo group lost just 3%, while standalone semaglutide 2.4 mg produced 16.1% weight loss, and standalone cagrilintide achieved 11.5%